Open an account

Halozyme Therapeutics

HALO · NASDAQ

$124.37+$1.87 (+1.53%)TodayMarket closed ·
Prev close $122.50

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 423 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED. The company also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.

Employees
423
Headquarters
San Diego, California
Listed
Jan 30, 2003
Sector
Health Care
Industry
Biotechnology
Website
halozyme.com

HALO key statistics

Market cap
13.90B
Price-earnings ratio
35.71
Dividend yield
—
Average volume
2.50M
Volume
2.15M
Open price
$123.54
High today
$125.10
Low today
$123.00
52 Week high
$123.60
52 Week low
$61.23

Halozyme Therapeutics (HALO) at a glance

As of Oct 20, 2026, Halozyme Therapeutics (HALO) shares are priced at $124.37, giving the company a market cap of 13.90B and a price-to-earnings ratio of 35.71.

Today the stock has traded between $123.00 and $125.10. The current price is 1.1% above the day's low and 0.6% below its high.

Volume so far is 2.15M shares, in line with the average of 2.50M shares a day.

Over the past year Halozyme Therapeutics has ranged from $61.23 to $123.60, and now sits 101% of the way up that range.

Halozyme Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $2.28 per share against an estimate of $1.87.

The average analyst price target is $106.01, 14.8% below the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

70%of 10 analyst ratings say Buy
  • Buy70.0%
  • Hold30.0%
  • Sell0.0%
Price target · 12 analystsAvg $106.01
Low
$88.88
Now
$124.37
High
$120.75

HALO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 13.6% on average.

  1. Q3 FY24: reported $1.27 per share against an estimate of $1.00
  2. Q4 FY24: reported $1.26 per share against an estimate of $1.18
  3. Q1 FY25: reported $1.11 per share against an estimate of $0.967
  4. Q2 FY25: reported $1.54 per share against an estimate of $1.29
  5. Q3 FY25: reported $1.72 per share against an estimate of $1.66
  6. Q4 FY25: reported -$0.24 per share against an estimate of $2.24
  7. Q1 FY26: reported $1.60 per share against an estimate of $1.56
  8. Q2 FY26: reported $2.28 per share against an estimate of $1.87

HALO news

  • Avi Kapoor

    Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday

  • Press releasePRNewswire

    Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets

  • Press releasePRNewswire

    Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

  • Press releasePRNewswire

    Halozyme Announces Appointment of Jim Daly to its Board of Directors

  • Press releasePRNewswire

    Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

  • Press releasePRNewswire

    Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033

  • Press releasePRNewswire

    Halozyme to Participate at Upcoming Investor Conferences

  • Press releasePRNewswire

    Halozyme Appoints Dannielle Appelhans to its Board of Directors

Similar companies

Companies in the same industry as Halozyme Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.